GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sucampo Pharmaceuticals Inc (NAS:SCMP) » Definitions » Sloan Ratio %

Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Sloan Ratio % : -1.11% (As of Sep. 2017)


View and export this data going back to 2007. Start your Free Trial

What is Sucampo Pharmaceuticals Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Sucampo Pharmaceuticals's Sloan Ratio for the quarter that ended in Sep. 2017 was -1.11%.

As of Sep. 2017, Sucampo Pharmaceuticals has a Sloan Ratio of -1.11%, indicating the company is in the safe zone and there is no funny business with accruals.


Sucampo Pharmaceuticals Sloan Ratio % Historical Data

The historical data trend for Sucampo Pharmaceuticals's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sucampo Pharmaceuticals Sloan Ratio % Chart

Sucampo Pharmaceuticals Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.97 17.42 -21.69 31.92 2.31

Sucampo Pharmaceuticals Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.90 2.31 -0.73 -6.14 -1.11

Competitive Comparison of Sucampo Pharmaceuticals's Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, Sucampo Pharmaceuticals's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sucampo Pharmaceuticals's Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sucampo Pharmaceuticals's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Sucampo Pharmaceuticals's Sloan Ratio % falls into.



Sucampo Pharmaceuticals Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Sucampo Pharmaceuticals's Sloan Ratio for the fiscal year that ended in Dec. 2016 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2016 )-Cash Flow from Operations (A: Dec. 2016 )
-Cash Flow from Investing (A: Dec. 2016 ))/Total Assets (A: Dec. 2016 )
=(18.487-8.313
--1.842)/520.851
=2.31%

Sucampo Pharmaceuticals's Sloan Ratio for the quarter that ended in Sep. 2017 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Sep. 2017 )
=(-150.893-28.506
--175.075)/388.144
=-1.11%

Sucampo Pharmaceuticals's Net Income for the trailing twelve months (TTM) ended in Sep. 2017 was 15.283 (Dec. 2016 ) + 4.624 (Mar. 2017 ) + -181.167 (Jun. 2017 ) + 10.367 (Sep. 2017 ) = $-150.9 Mil.
Sucampo Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2017 was -22.435 (Dec. 2016 ) + 45.28 (Mar. 2017 ) + 10.912 (Jun. 2017 ) + -5.251 (Sep. 2017 ) = $28.5 Mil.
Sucampo Pharmaceuticals's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2017 was -0.007 (Dec. 2016 ) + -0.35 (Mar. 2017 ) + -169.669 (Jun. 2017 ) + -5.049 (Sep. 2017 ) = $-175.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sucampo Pharmaceuticals  (NAS:SCMP) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Sep. 2017, Sucampo Pharmaceuticals has a Sloan Ratio of -1.11%, indicating the company is in the safe zone and there is no funny business with accruals.


Sucampo Pharmaceuticals Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Sucampo Pharmaceuticals's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Sucampo Pharmaceuticals Inc is a part of the healthcare sector in the United States. As a global pharmaceutical company, it commercializes drugs for the treatment of various gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It currently generates revenue mainly from product royalties, product sales, upfront and milestone payments, and reimbursements for development activities.
Executives
Peter Greenleaf officer: Chief Executive Officer ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Maureen Oconnell director
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Jones W. Bryan officer: Sr. Vice Pres., BD & Licensing C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Timothy P Walbert director 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Peter A Kiener officer: Chief Science Officer 40 GUEST STREET, BOSTON MA 02135
John Johnson director DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Peter P. Pfreundschuh officer: CFO C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paul R Edick director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Thomas J Knapp other: Former Officer 4640 SW MACADAM AVE., SUITE 270, PORTLAND OR 97239
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Timothy I Maudlin director 18739 VOGEL FARM TRAIL, EDEN PRAIRIE MN 55347
Nantahala Capital Management, Llc 10 percent owner 130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Mariam E Morris officer: Chief Acctg. Officer, Treas. C/O SUCAMPO PHARMACEUTICALS, 4520 EAST-WEST HIGHWAY, SUITE 300, BETHESDA MD 20814

Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Headlines